The Peter Lynch strategy, famously detailed in One Up on Wall Street, is built on a deceptively simple premise: invest in what you know and understand, and always seek strong, growing companies at a reasonable price. Unlike pure growth or value investors, Lynch looked for a blend—companies with sustainable earnings growth, solid financial health, and a valuation that hasn’t yet been bid up by the market. He advocated for patience, a long-term horizon, and a portfolio of 10 to 30 carefully selected names. The idea is to let the business’s fundamental performance drive returns over years, not months.
When we run a screen based on Lynch’s criteria, we filter for a specific set of conditions. The goal is to find companies with an EPS growth rate that is neither too hot nor too cold—ideally between 15% and 30% over the past five years. Additionally, the PEG ratio (which compares the price-to-earnings ratio to the earnings growth rate) must be at or below 1.0, ensuring the growth is not overpriced. Financial health is non-negotiable: debt-to-equity below 0.6, a current ratio above 1.0, and a return on equity exceeding 15% are all required.
Neurocrine Biosciences (NASDAQ:NBIX) emerges as a candidate from this screen, and its numbers speak directly to Lynch’s discipline. The company’s EPS growth over the past five years stands at 29.09%, falling comfortably within the ideal 15% to 30% band that Lynch favored. This is a sustainable clip—strong enough to signal momentum, but not so extreme that it raises red flags about short-lived hype. More importantly, the PEG ratio based on that past growth is 0.91, which is below the crucial 1.0 threshold. This is the essence of growth-at-a-reasonable-price: you are paying less than a dollar for each unit of earnings growth.
The financial health metrics reinforce the picture. Neurocrine carries zero debt on its balance sheet, giving it a debt-to-equity ratio of 0.0—well under the 0.6 ceiling and even below the stricter 0.25 level Lynch sometimes preferred. Its current ratio of 2.93 provides a wide margin of safety for short-term obligations, far exceeding the 1.0 minimum. Return on equity comes in at 19.62%, comfortably above the 15% benchmark. These are not merely passable numbers; they indicate a company with a strong foundation that can support future investment without relying on leverage.
Looking at the broader fundamental picture, Neurocrine Biosciences earns a rating of 7 out of 10 from the fundamental analysis report. The report highlights that the company scores highly in both profitability and health, while also showing excellent growth and valuation. In fact, the analysis notes that Neurocrine is both growing and still relatively cheap compared to its industry peers—a combination that is rare and aligns directly with the Lynch philosophy. The company’s operating margin of 25.75% and net profit margin of 21.55% place it well above the vast majority of its biotechnology peers, while its Altman-Z score of 8.66 signals a financially sound business with minimal bankruptcy risk.
For investors following the Lynch method, the key takeaway is that the criteria are designed to filter for quality and price simultaneously. Neurocrine meets each screen threshold by a clear margin, and its underlying business model—providing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders—fits the Lynch preference for understandable, specialty-focused companies. The company’s approved drugs like INGREZZA and Orilissa give it commercial traction, while its pipeline offers potential for continued, measured growth.
If this profile resonates with your approach, the full list of candidates that pass the Peter Lynch screen can be explored further. You can find additional potential opportunities by accessing the screener results.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance and screen results are not guarantees of future results. Always conduct your own research before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening
The Peter Lynch strategy, famously detailed in One Up on Wall Street, is built on a deceptively simple premise: invest in what you know and understand, and always seek strong, growing companies at a reasonable price. Unlike pure growth or value investors, Lynch looked for a blend—companies with sustainable earnings growth, solid financial health, and a valuation that hasn’t yet been bid up by the market. He advocated for patience, a long-term horizon, and a portfolio of 10 to 30 carefully selected names. The idea is to let the business’s fundamental performance drive returns over years, not months.
When we run a screen based on Lynch’s criteria, we filter for a specific set of conditions. The goal is to find companies with an EPS growth rate that is neither too hot nor too cold—ideally between 15% and 30% over the past five years. Additionally, the PEG ratio (which compares the price-to-earnings ratio to the earnings growth rate) must be at or below 1.0, ensuring the growth is not overpriced. Financial health is non-negotiable: debt-to-equity below 0.6, a current ratio above 1.0, and a return on equity exceeding 15% are all required.
Neurocrine Biosciences (NASDAQ:NBIX) emerges as a candidate from this screen, and its numbers speak directly to Lynch’s discipline. The company’s EPS growth over the past five years stands at 29.09%, falling comfortably within the ideal 15% to 30% band that Lynch favored. This is a sustainable clip—strong enough to signal momentum, but not so extreme that it raises red flags about short-lived hype. More importantly, the PEG ratio based on that past growth is 0.91, which is below the crucial 1.0 threshold. This is the essence of growth-at-a-reasonable-price: you are paying less than a dollar for each unit of earnings growth.
The financial health metrics reinforce the picture. Neurocrine carries zero debt on its balance sheet, giving it a debt-to-equity ratio of 0.0—well under the 0.6 ceiling and even below the stricter 0.25 level Lynch sometimes preferred. Its current ratio of 2.93 provides a wide margin of safety for short-term obligations, far exceeding the 1.0 minimum. Return on equity comes in at 19.62%, comfortably above the 15% benchmark. These are not merely passable numbers; they indicate a company with a strong foundation that can support future investment without relying on leverage.
Looking at the broader fundamental picture, Neurocrine Biosciences earns a rating of 7 out of 10 from the fundamental analysis report. The report highlights that the company scores highly in both profitability and health, while also showing excellent growth and valuation. In fact, the analysis notes that Neurocrine is both growing and still relatively cheap compared to its industry peers—a combination that is rare and aligns directly with the Lynch philosophy. The company’s operating margin of 25.75% and net profit margin of 21.55% place it well above the vast majority of its biotechnology peers, while its Altman-Z score of 8.66 signals a financially sound business with minimal bankruptcy risk.
For investors following the Lynch method, the key takeaway is that the criteria are designed to filter for quality and price simultaneously. Neurocrine meets each screen threshold by a clear margin, and its underlying business model—providing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders—fits the Lynch preference for understandable, specialty-focused companies. The company’s approved drugs like INGREZZA and Orilissa give it commercial traction, while its pipeline offers potential for continued, measured growth.
If this profile resonates with your approach, the full list of candidates that pass the Peter Lynch screen can be explored further. You can find additional potential opportunities by accessing the screener results.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance and screen results are not guarantees of future results. Always conduct your own research before making investment decisions.
Read full article here »